Literature DB >> 35737155

Prediction of EVT6-NTRK3-Dependent Papillary Thyroid Cancer Using Minor Expression Profile.

A A Kechin1, A A Ivanov2, A E Kel1, A S Kalmykov3, I P Oskorbin1, U A Boyarskikh1, E A Kharpov1, S Yu Bakharev2, N A Oskina1, O V Samuilenkova2, I V Vikhlyanov2, N E Kushlinskii4, M L Filipenko5.   

Abstract

Solid tumors resulting from oncogenic stimulation of neurotrophin receptors (TRK) by chimeric proteins are a group of rare tumors of various localization that respond to therapy with targeted drugs entrectinib and larotrectinib. The standard method for detecting chimeric TRK genes in tumor samples today is considered to be next generation sequencing with the determination of the prime structure of the chimeric transcripts. We hypothesized that expression of the chimeric tyrosine kinase proteins in tumors can determine the specific transcriptomic profile of tumor cells. We detected differentially expressed genes allowing distinguishing between TRK-dependent tumors papillary thyroid cancer (TC) from other molecular variants of tumors of this type. Using PCR with reverse transcription (RT-PCR), we identified 7 samples of papillary TC carrying a EVT6-NTRK3 rearrangement (7/215, 3.26%). Using machine learning and the data extracted from TCGA, we developed of a recognition function for predicting the presence of rearrangement in NTRK genes based on the expression of 10 key genes: AUTS2, DTNA, ERBB4, HDAC1, IGF1, KDR, NTRK1, PASK, PPP2R5B, and PRSS1. The recognition function was used to analyze the expression data of the above genes in 7 TRK-dependent and 10 TRK-independent thyroid tumors obtained by RT-PCR. On the test samples from TCGA, the sensitivity was 72.7%, the specificity - 99.6%. On our independent validation samples tested by RT-PCR, sensitivity was 100%, specificity - 70%. We proposed an mRNA profile of ten genes that can classify TC in relation to the presence of driver NTRK-chimeric TRK genes with acceptable sensitivity and specificity.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  ETV6-NTRK3; NTRK; chimeric proteins; thyroid cancer; transcription

Mesh:

Substances:

Year:  2022        PMID: 35737155     DOI: 10.1007/s10517-022-05528-w

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  9 in total

1.  Implications of the TCGA genomic characterization of papillary thyroid carcinoma for thyroid pathology: does follicular variant papillary thyroid carcinoma exist?

Authors:  Sylvia L Asa; Thomas J Giordano; Virginia A LiVolsi
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

2.  The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma.

Authors:  Xueyang Yang; Yifang Hu; He Shi; Chengzhou Zhang; Zhixiao Wang; Xiaoyun Liu; Huanhuan Chen; Lijuan Zhang; Dai Cui
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-06-27       Impact factor: 2.503

3.  Oncogenes in solid human tumours.

Authors:  S Pulciani; E Santos; A V Lauver; L K Long; S A Aaronson; M Barbacid
Journal:  Nature       Date:  1982-12-09       Impact factor: 49.962

4.  ETV6-NTRK3 and STRN-ALK kinase fusions are recurrent events in papillary thyroid cancer of adult population.

Authors:  André Uchimura Bastos; Ana Carolina de Jesus; Janete Maria Cerutti
Journal:  Eur J Endocrinol       Date:  2017-10-18       Impact factor: 6.664

5.  Molecular characterization of cancers with NTRK gene fusions.

Authors:  Zoran Gatalica; Joanne Xiu; Jeffrey Swensen; Semir Vranic
Journal:  Mod Pathol       Date:  2018-08-31       Impact factor: 7.842

Review 6.  NTRK fusion-positive cancers and TRK inhibitor therapy.

Authors:  Emiliano Cocco; Maurizio Scaltriti; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2018-12       Impact factor: 66.675

7.  Identification of novel long non-coding RNA biomarkers for prognosis prediction of papillary thyroid cancer.

Authors:  Qiuying Li; Haihong Li; Lu Zhang; Chunming Zhang; Wentao Yan; Chao Wang
Journal:  Oncotarget       Date:  2017-07-11

Review 8.  Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.

Authors:  Susan J Hsiao; Ahmet Zehir; Anthony N Sireci; Dara L Aisner
Journal:  J Mol Diagn       Date:  2019-05-07       Impact factor: 5.568

Review 9.  Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine.

Authors:  Stanislaw Supplitt; Pawel Karpinski; Maria Sasiadek; Izabela Laczmanska
Journal:  Int J Mol Sci       Date:  2021-01-31       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.